Apomorphine is a potent nonselective agonist at D1 and D2 dopamine receptors. The utility of apomorphine in Parkinson's disease (PD) is well asserted but its clinical use is reduced because of its short half-life and numerous side-effects. The disabling "on-off" fluctuations are among the most frequent and troublesome complications of chronic levodopa therapy in PD. Apomorphine is effective to reverse refractory L-dopa induced "off" periods, but a reduced motor response after repeated administrations has also been described with this drug. The loss of response to apomorphine, when the drug is administered repeatedly, is well fitted by the processes of receptor phosphorylation and down regulation. Elucidation of the molecular bases of dopaminergic receptors desensitization may lead to a better understanding of the mechanisms of dopaminergic regulation, and to a more appropriate treatment of PD.